Table 3.
Univariable, bivariable, and multivariable model results for the risk of no remission at 12 months using risk factors at a 3-month landmark time
| Risk Factors | Univariable or Bivariable Modelsa | Multivariable Model | ||
|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | |
| PLA2R antibody change from baseline to 3 mo (per RU/ml decrease)a | 0.97 (0.95 to 0.99) | 0.007 | 0.96 (0.93 to 0.98) | 0.002 |
| PLA2R antibody level at baseline (per RU/ml)a | 1.03 (1.01 to 1.05) | 0.008 | 1.04 (1.02 to 1.07) | 0.001 |
| Proteinuria change from baseline to 3 mo (per g/d decrease)a | 0.60 (0.47 to 0.75) | <0.001 | — | — |
| Proteinuria at baseline (per g/d)a | 1.42 (1.20 to 1.69) | <0.001 | — | — |
| Creatinine clearance at 3 mo >52 ml/min per 1.73 m2a | 0.12 (0.02 to 0.66) | 0.02 | 0.24 (0.02 to 2.81) | 0.26 |
| Creatinine clearance at baseline (per 10 ml/min per 1.73 m2 decrease)a | 1.08 (0.90 to 1.30) | 0.42 | 1.25 (0.92 to 1.69) | 0.16 |
| Albumin change from baseline to 3 mo (per 0.1 g/dl increase)a | 0.75 (0.65 to 0.87) | <0.001 | 0.71 (0.55 to 0.92) | 0.008 |
| Albumin at baseline (per 0.1 g/dl)a | 1.08 (0.99 to 1.19) | 0.09 | 1.02 (0.89 to 1.18) | 0.75 |
| Male sex | 3.1 (1.0 to 9.5) | 0.05 | 6.22 (0.81 to 47.6) | 0.08 |
| Prior immunosuppression use | 1.3 (0.5 to 3.5) | 0.56 | — | — |
| Treatment allocation to rituximab (versus cyclosporine) | 0.7 (0.3 to 1.8) | 0.49 | — | — |
OR, odds ratio; CI, confidence interval.
a
Variables with metrics at 3 months and at baseline were included together in bivariable models to adjust for baseline values.